Journal Article

FZJ-2020-01691

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Imaging findings following regorafenib in malignant gliomas: FET PET adds valuable information to anatomical MRI

Galldiks, N. (Corresponding author)FZJ* ; Werner, J.-M. ; Tscherpel, C. ; Fink, G. R.FZJ* ; Langen, K.-J.FZJ*

2019
Oxford University Press Oxford

This record in other databases:    

Please use a persistent id in citations: http://hdl.handle.net/2128/24699  doi:10.1093/noajnl/vdz038

Abstract: The prospective REGOMA phase 2 trial showed an encouraging and significant median progression-free and overall survival (PFS, OS) benefit for glioblastoma patients at first progression treated with the oral multikinase inhibitor regorafenib compared to lomustine monotherapy.1 In particular, the OS benefit was 1.8 months compared to lomustine (7.4 vs. 5.6 months; P = .0009), and the hazard ratio was 0.5 (95% confidence interval, 0.33–0.75). Interestingly, despite unchanged MRI findings at first follow-up (“Stable Disease,” 39%) following regorafenib, complete or partial radiological responses according to the RANO criteria2 were only seen in 5% of cases treated with regorafenib. On the other hand, 59% of patients in the regorafenib arm had grade 3–4 adverse events.

---

Contributing Institute(s):

1. Kognitive Neurowissenschaften (INM-3)
2. Physik der Medizinischen Bildgebung (INM-4)

Research Program(s):

1. 572 - (Dys-)function and Plasticity (POF3-572) (POF3-572)

Appears in the scientific report 2020

---

Database coverage:
;

---